34660 Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: Achievement of absolute PASI thresholds in the phase 3 POETYK PSO-1 and PSO-2 trials

Abstract

Background: Deucravacitinib is an oral selective inhibitor of TYK2, which mediates signaling of key cytokines in psoriasis immunopathogenesis. The efficacy of deucravacitinib in achieving Psoriasis Area and Severity Index (PASI) disease control thresholds in 2 Phase 3 trials was compared versus placebo and apremilast.